DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced clofazimine inhalation suspension (MNKD 101) will advance to an adaptive Phase 2/3 study. Additionally, a…
Mon, 23 Jan 2023 03:40:00 GMT Direct delivery of clofazimine to the lungs ... which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and ...
Mon, 23 Jan 2023 03:29:00 GMT Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation MNKD, a company focused on the development and commercialization of inhaled therapeutic products ... health and the freedom to live life. This ...
Mon, 23 Jan 2023 03:07:00 GMT Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products ... and the freedom to live life. This ...
Sun, 22 Jan 2023 16:00:00 GMT "We are encouraged by the preclinical and Phase 1 data, and how inhaled ... press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind ...
